Novacyt S.A. (NVYTF)
| Market Cap | 32.56M -20.9% |
| Revenue (ttm) | 26.65M +39.5% |
| Net Income | -41.65M |
| EPS | -0.60 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Average Volume | 758 |
| Open | 0.4800 |
| Previous Close | 0.5101 |
| Day's Range | 0.4800 - 0.4800 |
| 52-Week Range | 0.4800 - 0.6410 |
| Beta | 1.06 |
| RSI | 40.97 |
| Earnings Date | Apr 30, 2026 |
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the... [Read more]
Financial Performance
In 2024, Novacyt's revenue was 19.63 million, an increase of 84.82% compared to the previous year's 10.62 million. Losses were -41.76 million, 47.6% more than in 2023.
Financial numbers in GBP Financial StatementsNews
Novacyt makes Australian acquisition to accelerate global growth
Novacyt's acquisition of Southern Cross Diagnostics via its wholly owned subsidiary will give it a bigger overseas footprint.
Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Half Year 2022 Results
PARIS & CAMBERLEY, England--(BUSINESS WIRE)--Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited results for the ...